MediciNova Inc - Asset Resilience Ratio
MediciNova Inc (MNOV) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of MediciNova Inc to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2003–2023)
This chart shows how MediciNova Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see MediciNova Inc (MNOV) total assets.
Liquid Assets Composition Over Time
This chart breaks down MediciNova Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore investment intensity of MediciNova Inc to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: MediciNova Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
MediciNova Inc Industry Peers by Asset Resilience Ratio
Compare MediciNova Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for MediciNova Inc (2003–2023)
The table below shows the annual Asset Resilience Ratio data for MediciNova Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $66.27 Million | -- |
| 2022-12-31 | 53.92% | $39.98 Million | $74.15 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $87.41 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $43.42 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $39.81 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $37.91 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $27.27 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $29.55 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $19.57 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $30.79 Million | -- |
| 2010-12-31 | 0.86% | $623.75K | $72.93 Million | -27.57pp |
| 2009-12-31 | 28.42% | $26.81 Million | $94.33 Million | -41.89pp |
| 2007-12-31 | 70.31% | $51.86 Million | $73.75 Million | -15.46pp |
| 2006-12-31 | 85.77% | $95.72 Million | $111.59 Million | +14.83pp |
| 2005-12-31 | 70.95% | $101.02 Million | $142.39 Million | +48.63pp |
| 2004-12-31 | 22.32% | $12.00 Million | $53.77 Million | +0.12pp |
| 2003-12-31 | 22.20% | $1.25 Million | $5.63 Million | -- |
About MediciNova Inc
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis… Read more